Amgen Inc. (AMGN) Latest Stock News & Headlines - Yahoo Finance
WEBGet the latest Amgen Inc. (AMGN) stock news and headlines to help you in your trading and investing decisions.
AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS …
WEBTHOUSAND OAKS, Calif., Oct. 6, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.
News | Amgen
WEBAMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD) 06.03.2024. AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE.
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY ... - Amgen
WEBMay 16, 2024 · FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER. Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor. IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 …
Amgen quarterly profit rises 15%, obesity drug trials are on track
WEBFeb 6 (Reuters) - Amgen (AMGN.O) on Tuesday said its adjusted fourth-quarter profit rose 15%, driven by a 20% increase in revenue following the biotechnology company's October acquisition of...
Amgen Seeks Expanded US Approval For Autoimmune Disease …
WEBJun 5, 2024 · On Wednesday, Amgen Inc (NASDAQ: AMGN) announced topline results from its Phase 3 trial evaluating the efficacy and safety of Uplizna (inebilizumab-cdon) for Immunoglobulin G4-related disease, a...
Amgen dives deeper into rare disease drugs with $27.8 bln …
WEBDec 12, 2022 · Amgen shares dipped less than 1% to close at $276.78. With the deal, Amgen gains two fast-growing drugs, the thyroid eye disease treatment Tepezza and gout treatment Krystexxa.
Amgen Agrees to Acquire Horizon Therapeutics for $27.8 Billion
WEBDec 12, 2022 · Amgen Inc. AMGN -2.00% agreed to acquire Horizon Therapeutics PLC for $27.8 billion, marking the largest healthcare merger of the year.
Press Releases - Amgen Inc.
WEBAug 29, 2024 · news release 06.05.2024. amgen announces positive results for phase 3 registrational trial evaluating uplizna® (inebilizumab-cdon) for treatment of immunoglobulin g4-related disease (igg4-rd)
Amgen to buy Horizon Therapeutics in $26.4 billion deal
WEBDec 12, 2022 · Amgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare, autoimmune diseases, in a deal valued at approximately $26.4 billion. Each Horizon...
Skip to content